Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka)
Study Drug: The experimental drug is an inhibitor of the enzyme phosphodiesterase 4 (PDE4) administered in inhalation form. This group of drugs is already registered in tablet form, and now the anti-inflammatory effectiveness of the drug is being investigated when administered as an inhalation.
Main Inclusion Criteria: Patients aged 40 and older with a diagnosis of COPD at any time in the past, who are on a triple inhalation therapy with a stable dose for at least 3 months, and who have had at least one severe exacerbation of the disease (flare-up) in the last year, requiring a visit to the doctor.
Status: Enrolling new patients
Start of patient enrollment: February 2023
End of patient enrollment: October 2024
